Skip to content

Trophoblast cell-surface antigen 2-directed enhancement of gene delivery using a nanobody-engineered recombinant adeno-associated virus for bispecific T-cell engager-mediated T-cell cytotoxicity in triple-negative breast cancer cells.

Nov 2026 · International Journal of Biological Macromolecules · pp. 155185 · 0 citations · 23 references
Medicine

TL;DR

RAAV-Nb was used to deliver the BiTE transgene, resulting in robust T-cell activation and potent BiTE-mediated T-cell cytotoxicity against TROP2-positive TNBC cells in vitro.

Abstract

Triple-negative breast cancer (TNBC) poses a significant therapeutic challenge because it has limited actionable molecular targets. Trophoblast cell-surface antigen 2 (TROP2) is a promising therapeutic target, overexpressed in approximately 80% of TNBC cases. However, conventional recombinant adeno-associated virus (rAAV) vectors exhibit broad natural tropism, which limits selective gene delivery to TROP2-positive tumor cells. In this study, we developed a TROP2-directed capsid-engineered rAAV platform designed to incorporate a TROP2-specific nanobody through genetic insertion into the VP1 capsid protein. Through phage display selection, we identified K118.1, a nanobody with nanomolar affinity, efficient internalization following TROP2 binding, and cross-reactivity with both human and mouse TROP2. We then generated a TROP2-directed capsid-engineered vector (rAAV-Nb) by genetically inserting K118.1 into the GH2/GH3 loop of the rAAV6 VP1 subunit. Compared with the parental rAAV6 vector, rAAV-Nb increased BiTE transgene expression by approximately 3- to 6-fold in TROP2-positive TNBC cells. GFP reporter analyses further demonstrated that TROP2 engagement contributes to the enhanced transduction mediated by rAAV-Nb. As a proof-of-concept therapeutic application, rAAV-Nb was used to deliver the BiTE transgene, resulting in robust T-cell activation and potent BiTE-mediated T-cell cytotoxicity against TROP2-positive TNBC cells in vitro. Epitope mapping and structural modeling indicated that K118.1 recognizes a conformation-dependent epitope within hTROP2, providing molecular insight into target recognition. Collectively, these findings suggest that nanobody-guided capsid engineering represents a promising strategy to enhance rAAV-mediated transgene delivery to TROP2-expressing cancer cells.

View source

Similar papers

Open access Sep 2026

Dendritic-cell-targeting adeno-associated virus as potent cancer vaccine carriers

This study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.

Xin Wei, Xiang Li, Li-Xia Qi et al. · 0 citations
Open access Sep 2026

Development of a Recombinant Adeno-Associated Virus Vector for Human T Lymphocyte- and Natural Killer Cell-Targeted Gene Therapy.

A CD7-targeted rAAV vector featuring a nanobody-fused hybrid capsid derived from a rationally selected chimeric combination of AAV6 and AAV9 establishes an integrated capsid-genome design framework for targeting human T and NK cells, notoriously challenging immune cell populations for gene therapy, and provides a versa...

H. Jahnz, M. V. Hamann, H. Kim et al. · 0 citations
#protein folding Open access Nov 2026

CD3scFv-Engineered AAV Capsid Drives Superior In Vitro and In Vivo CAR-T Cell Generation and Leads to Complete Eradication of CD19+ Tumors.

It is demonstrated that site-selective CD3scFv insertion into a single AAV capsid protein provides a robust, versatile platform for improved T cell transduction and effective in vivo CAR-T cell generation, offering a promising off-the-shelf approach for treating B cell malignancies.

Hai-Feng Chen, T. Hoang, A. Smith et al. · 0 citations
Open access

Production and efficacy test of a recombinant fluorescence-labelled single chain variable fragment against trophoblast cell surface antigen 2 protein in vitro

Trophoblast cell surface antigen 2 (Trop2) is a transmembrane glycoprotein encoded by the single-exon gene tumor-associated calcium signal transducer 2 (TACSTD2) gene and was first identified in human placental trophoblasts. Trop2 expression was detected in widely distributed healthy epithelial cells of many organs. A...

Ratanapa Phetchai · 0 citations
Open access Oct 2026

Single-domain antibody-conjugated lipid nanoparticles for selective mRNA delivery to CD4⁺ T cells and Brec1-mediated excision of HIV-1 proviral DNA

Approaches to curing HIV infection aim to eliminate the latent viral reservoir — long-lived, resting CD4⁺ T cells harboring integrated but transcriptionally silent proviral DNA — which persists despite effective antiretroviral therapy. The HIV-1 LTR-specific designer-recombinase Brec1 can precisely excise integrated pr...

Melanie Wittner, P. Hartjen, Oliver Keil et al. · 0 citations
Open access Oct 2026

Discovery and Optimization of the Novel Immunotoxins Targeting TROP2 for Cancer Therapy

The therapeutic potential of these novel anti-TROP2 immunotoxins against TROP2-overexpressing tumors is demonstrated and five doses of either dsT3PE or dsT3PE_ABD_CC at 3 mg/kg could significantly reduce tumor progression in the NCI-N87 mouse xenograft model.

Jun-Yan Li, Tanja Poredoš, Shu-Yi Xu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.